NasdaqGS:AMGNBiotechs
What Could Amgen (AMGN) Gain From Tezspire’s Phase III EoE Success?
Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase III results for Tezspire in eosinophilic esophagitis, supporting a potential label expansion.
The data are expected to support regulatory submissions for Tezspire as a treatment option in eosinophilic esophagitis.
A successful label expansion could open a broader market opportunity and place Tezspire in direct competition with an established eosinophilic esophagitis therapy.
Amgen is far from the only company tied to the growing...